Symbiotec Pharmalab Limited (NSE:SYMBIOTEC)

Market Cap	69.28B
Revenue (ttm)	8.69B +27.5%
Net Income	1.10B +41.7%
EPS	19.00 +34.0%
Shares Out	64.26M
PE Ratio	56.75
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	663,761
Open	1,068.00
Previous Close	1,078.25
Day's Range	1,068.00 - 1,133.60
52-Week Range	934.20 - 1,180.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Symbiotec Pharmalab

Symbiotec Pharma Lab Pvt. Ltd. develops, manufactures, and markets active pharmaceutical ingredients (APIs), with a primary focus on cortico-steroids and steroid-hormone APIs in both sterile and non-sterile forms. The company synthesizes progestin, estrone, testosterone, their derivatives, and anabolic steroids, supplying these in commercial volumes globally. It offers APIs and intermediate pharmaceutical products for therapeutic areas such as gastrointestinal ailments, cardiovascular disease, pain management, paediatrics, anti-infective, and d...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1995
• Employees: 1,752
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: SYMBIOTEC

Financial Performance

In fiscal year 2026, Symbiotec Pharmalab's revenue was 8.69 billion, an increase of 15.65% compared to the previous year's 7.52 billion. Earnings were 1.10 billion, an increase of 13.53%.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Sep 7, 2026

Data Sources Report a data error